Department of Public Health, College of Health Sciences, QU Health, Qatar University, Doha, PO BOX 2713, Qatar.
ANU Medical School, Australian National University, Canberra, ACT 2601, Australia.
J Travel Med. 2021 Jul 7;28(5). doi: 10.1093/jtm/taab057.
Chemoprophylaxis with weekly doses of tafenoquine (200 mg/day for 3 days before departure [loading dose], 200 mg/week during travel and 1-week post-travel [maintenance doses]) is effective in preventing malaria. Effectiveness of malaria chemoprophylaxis drugs in travellers is often compromised by poor compliance. Shorter schedules that can be completed before travel, allowing 'drug-free holidays', could increase compliance and thus reduce travel-related malaria. In this meta-analysis, we examined if a loading dose of tafenoquine alone is effective in preventing malaria in short-term travellers.
Four databases were searched in November 2020 for randomized controlled trials (RCTs) that assessed efficacy and/or safety of tafenoquine for chemoprophylaxis. Network meta-analysis using the generalized pair-wise modelling framework was utilized to estimate the odds ratio (OR) of malaria infection in long-term (>28 days) and short-term (≤28 days) travellers, as well as adverse events (AEs) associated with receiving loading dose of tafenoquine alone, loading dose of tafenoquine followed by maintenance doses, loading dose of mefloquine followed by maintenance doses, or placebo.
Nine RCTs (1714 participants) were included. In long-term travellers, compared to mefloquine, tafenoquine with maintenance doses (OR = 1.05; 95% confidence interval [CI]: 0.44-2.46) was equally effective in preventing malaria, while there was an increased risk of infection with the loading dose of tafenoquine alone (OR = 2.89; 95% CI: 0.78-10.68) and placebo (OR = 62.91; 95% CI: 8.53-463.88). In short-term travellers, loading dose of tafenoquine alone (OR = 0.98; 95% CI: 0.04-22.42) and tafenoquine with maintenance doses (OR = 1.00; 95% CI: 0.06-16.10) were as effective as mefloquine. The risk of AEs with tafenoquine with maintenance doses (OR = 1.03; 95% CI: 0.67-1.60) was similar to mefloquine, while loading dose of tafenoquine alone (OR = 0.58; 95% CI: 0.20-1.66) was associated with lower risk of AEs, although the difference was not statistically significant.
For short-term travellers, loading dose of tafenoquine alone was equally effective, had possibly lower rate of AEs, and likely better compliance than standard tafenoquine or mefloquine chemoprophylaxis schedules with maintenance doses. Studies are needed to confirm if short-term travellers remain free of infection after long-term follow-up.
The meta-analysis was registered in PROSPERO (CRD42021223756).
Tafenoquine is the latest approved drug for malaria chemoprophylaxis. A loading dose of tafenoquine (200 mg/day for 3 days before departure) is as effective in preventing malaria in short-term (≤28 days) travellers as chemoprophylaxis schedules of tafenoquine or mefloquine with maintenance doses, allowing travellers to have a 'drug-free holiday'.
每周服用一次磷酸萘酚喹(出发前 3 天每天 200mg[负荷剂量],旅行期间每周 200mg 和旅行后 1 周[维持剂量])进行化学预防可有效预防疟疾。由于用药依从性差,旅行者使用抗疟药化学预防的效果往往受到影响。能够在旅行前完成、允许“无药假期”的更短疗程可能会提高用药依从性,从而减少与旅行相关的疟疾。在这项荟萃分析中,我们研究了仅服用负荷剂量的磷酸萘酚喹是否能有效预防短期旅行者患疟疾。
在 2020 年 11 月检索了四个数据库,以评估磷酸萘酚喹用于化学预防的疗效和/或安全性的随机对照试验(RCT)。使用广义成对模型框架进行网络荟萃分析,以估计长期(>28 天)和短期(≤28 天)旅行者疟疾感染的优势比(OR),以及与单独服用负荷剂量的磷酸萘酚喹、磷酸萘酚喹加维持剂量、甲氟喹加维持剂量或安慰剂相关的不良事件(AE)。
纳入了 9 项 RCT(1714 名参与者)。与甲氟喹相比,在长期旅行者中,服用磷酸萘酚喹加维持剂量(OR=1.05;95%置信区间[CI]:0.44-2.46)在预防疟疾方面同样有效,而单独服用磷酸萘酚喹负荷剂量(OR=2.89;95%CI:0.78-10.68)和安慰剂(OR=62.91;95%CI:8.53-463.88)的感染风险增加。在短期旅行者中,单独服用磷酸萘酚喹负荷剂量(OR=0.98;95%CI:0.04-22.42)和服用磷酸萘酚喹加维持剂量(OR=1.00;95%CI:0.06-16.10)与服用甲氟喹的效果相同。服用磷酸萘酚喹加维持剂量(OR=1.03;95%CI:0.67-1.60)的 AE 风险与服用甲氟喹相似,而单独服用磷酸萘酚喹负荷剂量(OR=0.58;95%CI:0.20-1.66)与 AE 风险降低相关,尽管差异无统计学意义。
对于短期旅行者,单独服用磷酸萘酚喹负荷剂量与标准的磷酸萘酚喹或甲氟喹化学预防加维持剂量方案同样有效,可能具有更低的 AE 发生率,并且可能具有更高的用药依从性。需要进一步的研究来确认短期旅行者在长期随访后是否仍然没有感染。
该荟萃分析在 PROSPERO(CRD42021223756)中进行了注册。
磷酸萘酚喹是最新批准的疟疾化学预防药物。在短期(≤28 天)旅行者中,服用磷酸萘酚喹负荷剂量(出发前 3 天每天 200mg)与磷酸萘酚喹或甲氟喹加维持剂量的化学预防方案同样有效,允许旅行者度过“无药假期”。